Project
A 24 week, randomized, double-blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in pulmonary arterial hypertension (PAH)
Aborted · 2012 until 2014
Burger Barbara, Haider Karin, Brutsche Martin